Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Dose Optimized, Open Label, Evaluation of the Effect Foquest® (Methylphenidate HCl Controlled Release) on Sleep in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder

NCT04741516 is registered in ClinicalTrials.gov with JPM van Stralen Medicine Professional as lead sponsor.

NCT NCT04741516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04741516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Dose Optimized, Open Label, Evaluation of the Effect Foquest® (Methylphenidate HCl Controlled Release) on Sleep in Children Aged 6-12 With Attention Deficit Hyperactivity Disorder
Lead sponsor
JPM van Stralen Medicine Professional
Phase
Phase 4
Overall status
Unknown status
Start date
December 1, 2020
Completion date
December 31, 2023
Enrollment
41 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

attention deficit hyperactivity disorder